Release Date: February 11, 1999

PA NUMBER:  PAR-99-063


National Cancer Institute

This program announcement (PA) replaces PAR-96-046, which was published in the
Nih Guide, Vol. 25, No. 13, April 26, 1996.


The goal of the National Cancer Institute's (NCI) Howard Temin Award is to
bridge the transition from a mentored research environment to an independent
research career for scientists who have demonstrated unusually high potential
during their initial stages of training and development.  This special award
is aimed at fostering the research careers of outstanding junior  scientists
in basic research who are committed to developing research programs highly
relevant to the understanding of human biology and human disease as it relates
to the etiology, pathogenesis, prevention, diagnosis, and treatment of human
cancer.  The major objective of the award is to sustain and advance the early
research careers of the most promising M.D.s and Ph.D.s while they consolidate
and focus their independent research programs, and obtain their own research
grant support.  To achieve this objective, the Howard Temin Award offers
candidates up to five years to develop knowledge in the basic sciences and
research skills relevant to the candidate's career goals, with up to three of
the initial years (at least one year required) in a mentored environment
followed by a transition to an unmentored independent investigator phase for
the remaining time on the award.


The Public Health Service (PHS) is committed to achieving the health promotion
and disease prevention objectives of "Healthy People 2000," a PHS-led national
activity for setting priority areas.  This PA, The Howard Temin Award, is
related to the priority area of  human resource development.  Potential
applicants may obtain a copy of "Healthy People 2000" (Full Report:  Stock No.
017-001-00474-0 or Summary Report:  Stock No. 017-001-00473-1) through the
Superintendent of Documents, Government Printing Office, Washington, DC
20402-9325 (telephone 202-512-1800), or electronically


Applicants are encouraged to contact the NCI program staff listed under
INQUIRIES regarding their eligibility for this award prior to the preparation
of an application.

The candidate must have a research or a health professional doctorate or its
equivalent, must have completed at least three years of postdoctoral research
at the time of award, and must have demonstrated highly productive research
activity and the potential for establishing an independent research program in
the period after the doctorate.  Recipients of an NCI Preventive Oncology/
Population Sciences Career Development (K07) Award, a Mentored Clinical
Research Scientist Career Development (K08) Award or a Mentored Patient-
Oriented Research Career Development (K23) Award who are in their last two
years of support are also eligible to apply.  The career development award
will be terminated upon acceptance of a Howard Temin Award.

Candidates must be able to identify an individual who can serve as a mentor
for some portion of the initial mentored phase of this award.

Former principal investigators on any NIH research grants or non-PHS peer
reviewed grants that are over $70,000 direct costs per year are not eligible
to apply.  A candidate submitting an application for the Howard Temin Award
may not simultaneously submit an application for any other PHS award that
duplicates the provisions of this award nor have another application pending

Applications may be submitted, on behalf of candidates, by domestic,
non-Federal organizations, public or private, such as medical, dental, or
nursing schools or other institutions of higher education. Racial/ethnic
minority individuals, women, and persons with disabilities are encouraged to
apply as principal investigators.  Candidates must be U.S. citizens or
non-citizen nationals, or must have been lawfully admitted for permanent
residence by the time of award.  Individuals admitted for permanent residence
must be able to produce documentation of their immigration status such as an
Alien Registration Receipt Card (I-151 or I-551) or some other verification of
legal admission as a permanent resident.  Non-citizen nationals, although not
U.S. citizens, owe permanent allegiance to the U.S.  They are usually born in
lands that are not states but are under U.S. sovereignty, jurisdiction, or
administration.  Individuals on temporary or student visas are not eligible
for this award.


This PA will use the National Institutes of Health (NIH) K01 mechanism.  The
total project period for an application submitted in response to this PA may
not exceed 5 years.  The actual length of the awarded project period will
depend upon the number of years of prior research experience and the need for
additional experiences to achieve independence.  Planning, direction, and
execution of the program will be the responsibility of the candidate and
her/his mentor on behalf of the applicant institution.  Awards are not


The Howard Temin award is a highly competitive award, with the intent of
providing support to outstanding junior scientists during their transition to
an independent investigator status.  Consequently, the National Cancer
Institute expects to make only approximately ten awards each year.


A.  Purpose: The National Cancer Institute is interested in encouraging basic
scientists to become more interested in research problems of high relevance to
human biology particularly as they relate to the etiology, pathogenesis,
prevention, diagnosis, control and treatment of human cancer.  In the past,
the major effort of the NCI has been to encourage medically trained
individuals to become interested in basic research problems at the most
fundamental biological levels, but there has been no effort to encourage
scientists trained in the basic sciences to focus on problems of direct
relevance to the clinical sciences or the prevention, control and population
sciences.  The continued success of future cancer research will depend upon
the increased ability of the cancer biomedical research community to
effectively translate observations in the laboratory into patient and
population research settings.  Well-trained basic scientists who focus their
research on human biology and human disease will be an essential component of
the translational research enterprise.  The Howard Temin Award not only offers
continuing encouragement to clinicians for training in basic research, but
additionally represents a complementary new effort to encourage scientists
trained in the basic sciences to focus on problems of direct high relevance to
the clinical sciences or the prevention, control and population sciences as
they relate to cancer. Specifically, the Howard Temin Award provides an
opportunity for medically trained individuals and basic scientists to
initially work under a mentor in an institutional environment that will enable
them to transition to an independent research position and acquire research
support focused on issues and problems highly relevant to human cancer.

B.  Environment: The institution must have a well-established basic research
and/or clinical career development program(s) and qualified faculty to serve
as mentors.  The candidate, mentor and institution must be able to describe a
multi-disciplinary career development program in basic research that will
maximize the use of relevant research and educational resources.

C. Program: The award provides up to five consecutive 12 month appointments. 
At least 75 percent of the recipient's full-time professional effort must be
devoted to the program and the remainder devoted to other research-related
and/or teaching pursuits consistent with the objectives of the award.  The
candidate must develop knowledge in the basic sciences and research skills
relevant to his or her career goals.  The candidate may find it appropriate to
include relevant didactic and laboratory or field research experiences.

D.  Mentor(s): The recipient must receive appropriate mentoring during some
fraction of the first three years of the initial phase of the award.  The
candidate may move to an unmentored research environment beginning with any
time within the first year.  However, the transition must take place no later
than the end of the third year.  Where feasible, women and minority mentors
should be involved as role models.

E.  Allowable Costs:

1.  Salary: The Temin award will provide salary up to $75,000 plus fringe
benefits.  The total salary requested must be based on a full-time, 12 month,
staff appointment requiring the candidate to spend a minimum of 75 percent
effort conducting cancer research with the remaining effort being devoted to
activities related to the development of a successful research career.  The
salary must be consistent both with the established salary structure at the
institution and with salaries actually provided by the institution from its
own funds to other staff members of equivalent qualifications, rank, and
responsibilities in the department concerned.  If full-time, 12 month salaries
are not currently paid to comparable staff members, the salary proposed must
be appropriately related to the existing salary structure.

2.  Research Development Support: During the mentored phase of the award,
$30,000 per year will be provided for the following types of expenses: (a)
research expenses, such as supplies, equipment, and technical personnel; (b)
statistical services including personnel and computer time; (c) tuition, fees,
and books related to career development; and (d) travel to research meetings
or for training.  The amount of this support will increase to $50,000 when the
principal investigator transitions to an independent research position either
at the same institution or at a different institution.

3.  Ancillary Personnel Support: Salary for mentors, secretarial and
administrative assistance, etc. is not allowed.

4. Facilities and Administrative Costs:  These costs, which were formerly
called indirect costs, will be reimbursed at 8 percent of modified total
direct costs.

F. Evaluation:  In carrying out its stewardship of human resource related
programs, the NIH may begin requesting information essential to an assessment
of the effectiveness of this program.  Accordingly, recipients are hereby
notified, that they may be contacted after the completion of this award for
periodic updates on various aspects of their employment history, publications,
support from research grants or contracts, honors and awards, professional
activities, and other information helpful in evaluating the impact of the

G. Other Income: Fees resulting from clinical practice, professional
consultation, or other comparable activities required by the research and
research-related activities of this award may not be retained by the career
award recipient.  Such fees must be assigned to the grantee institution for
disposition by any of the following methods:

o The funds may be expended by the grantee institution in accordance with the
NIH policy on supplementation of career award salaries and to provide fringe
benefits in proportion to such supplementation. Such salary supplementation
and fringe benefit payments must be within the established policies of the
grantee institution;
o The funds may be used for health-related research purposes;
o The funds may be paid to miscellaneous receipts of the U.S. Treasury. Checks
should be made payable to the Department of Health and Human Services, NIH and
forwarded to the Director, Division of Financial Management, NIH, Bethesda,
Maryland 20892.  Checks must identify the relevant award account and reason
for the payment;
o Awardees may retain royalties and fees for activities such as scholarly
writing, service on advisory groups, or honoraria from other institutions for
lectures or seminars, provided these activities remain incidental and provided
that the retention of such pay is consistent with the policies and practices
of the grantee institution.

Usually, funds budgeted in an NIH supported research or research training
grant for the salaries or fringe benefits of individuals, but freed as a
result of a career award, may not be rebudgeted.  The awarding component will
give consideration to approval for the use of released funds only under
unusual circumstances.  Any proposed retention of funds released as a result
of a career award must receive prior written approval of the NIH awarding

H. Special Leave: Leave to another institution, including a foreign laboratory
may be permitted if the proposed experience is directly related to the purpose
of the award.  Only local, institutional approval is required if such leave
does not exceed 3 months.  For longer periods, prior written approval of the
NIH funding component is required.  To obtain prior approval, the award
recipient must submit a letter to the NIH funding component describing the
plan, countersigned by his or her department head and the appropriate
institutional official.  A copy of a letter or other evidence from the
institution where the leave is to be taken must be submitted to assure that
satisfactory arrangements have been made.  Support from the career award will
continue during such leave.

Leave without award support may not exceed 12 months.  Such leave requires the
prior written approval of the NIH funding component and will be granted only
in unusual situations.  Support from other sources is permissible during the
period of leave.  Such leave does not reduce the total number of months of
program support for which an individual is eligible.

Under unusual and pressing circumstances, an awardee may submit a written
request to the awarding component, requesting a reduction in professional
effort below 75 percent.  Such requests will be considered on a case-by-case
basis during the award period.  In no case, will it be permissible to work at
a rate of less than 50 percent effort.  The nature of the circumstances
requiring reduced effort might include medical conditions, disability, or
pressing personal or family situations such as child or elder care. 
Permission to reduce the level of effort will not be approved to accommodate
other sources of funding, job opportunities, clinical practice, or clinical
training.  In each situation, the grantee institution must submit
documentation supporting the need for reduced effort along with assurance of a
continuing commitment to the scientific development of the awardee.  Further,
the  awardee must submit assurance of his or her intention to return to
full-time professional effort (at least 75 percent) as soon as possible. 
During the period of reduced effort, the salary and other costs supported by
the award will be reduced accordingly.

I. Termination or Change of Institution:  When a grantee institution plans to
terminate an award, the NIH funding component must be notified in writing at
the earliest possible time so that appropriate instructions can be given for
termination. The Director of the NIH may discontinue an award upon
determination that the purpose or terms of the award are not being fulfilled. 
In the event an award is terminated, the Director of the NIH shall notify the
grantee institution and career award recipient in writing of this
determination, the reasons therefor, the effective date, and the right to
appeal the decision.

Awardees planning a change of institution, must submit to the funding NIH
component in advance of the change a written request for transfer,
countersigned by the appropriate institutional business official, describing
the reasons for the change and including the new sponsor's name and biosketch. 
The awardee must establish in this request that the specific aims of the
research program to be conducted at the new institution are within the scope
of the original peer reviewed research program.  Additionally, the new sponsor
must have the appropriate research expertise to supervise the program and
sufficient research  support to ensure continuation of the research program to
the end of the award (initial award).  Staff within the NIH funding component
will review this request and may require a review by an initial review group
and/or the appropriate National Advisory Council or Board. Upon approval of
this request, a new career award application must be submitted by the new
institution far enough in advance of the requested effective date to permit
review.  The period of support requested in the new application must be no
more than the time remaining within the existing award period.

When a mentor at the grantee institution is to be replaced, the institution
must submit a letter from the proposed mentor documenting the need for
substitution, the new mentor's qualifications for supervising the program, and
the level of support for the candidate's career development.  The letter must
also document that the specific aims of the research program will remain
within the scope of the original peer reviewed research program.  Staff within
the NIH funding component will review the request, and will notify the grantee
institution of the results of the evaluation..

A final progress report, invention statement, and Financial Status Report are
required upon either termination of an award or relinquishment of an award in
a change of institution situation.


It is the policy of the NIH that women and members of minority groups and
their subpopulations must be included in all NIH supported biomedical and
behavioral research projects involving human subjects unless a clear and
compelling rationale and justification is provided that inclusion is
inappropriate with respect to the health of the subjects or the purpose of the
research.  This policy results from the NIH Revitalization Act of 1993
(Section 492B of Public Law 103-43).

All investigators proposing research involving human subjects should read the
"NIH Guidelines For Inclusion of Women and Minorities as Subjects in Clinical
Research," which has been published in the Federal Register of March 20, 1994
(FR 59 14508-14513), and in the NIH Guide for Grants and Contracts, Volume 23,
Number 11, March 18, 1994 available electronically at

Investigators may obtain copies from these sources or from the program staff
or contact person listed under INQUIRIES.  Program staff may also provide
additional relevant information concerning the policy.


It is the policy of NIH that children (i.e., individuals under the age of 21)
must be included in all human subjects research, conducted or supported by
NIH, unless there are clear and compelling scientific and ethical reasons not
to include them. This policy applies to all initial (Type 1) applications
submitted for receipt dates after October 1, 1998.

All investigators proposing research involving human subjects should read the
"NIH Policy and Guidelines on the Inclusion of Children as Participants in
Research Involving Human Subjects" that was published in the NIH GUIDE FOR
GRANTS AND CONTRACTS, March 6, 1998 and is available at the following URL


Applications are to be submitted on the grant application form PHS 398 (rev.
4/98) and should use the instructions in Section IV of the application kit. 
Allocations will be accepted at the standard application deadlines as
indicated in the application kit.  Application kits are available at most
institutional offices of sponsored research and from the Division of
Extramural Outreach and Information Resources, National Institutes of Health,
6701 Rockledge Drive, MSC 7910, Bethesda, MD 20892-7910, telephone
301/710-0267, Email:  The title and number of the program
announcement must be typed in Section 2 on the face page of the application
form and the YES box must be marked.  Application kits are also available on
the world wide web at:

The completed original application and three legible copies must be sent or
delivered to:

6701 ROCKLEDGE DRIVE, ROOM 1040 - MSC 7710
BETHESDA, MD  20892-7710
BETHESDA, MD  20817 (for express/courier service)

At the time of submission, two additional copies of the application must be
sent to:

Ms. Toby Friedberg
Division of Extramural Activities
National Cancer Institute
6130 Executive Boulevard, Room 626
Bethesda, MD  20892-7407
Rockville, MD 20852 (for express/courier service)

The application must address the following issues and include the following


o  Describe the candidate's commitment to a career in basic biomedical
research highly relevant to human biology and cancer (candidates interested in
patient-oriented  research should consider the Mentored, Patient-Oriented
Research Career Development Award (K23);
o  Present evidence of the candidate's ability to interact and collaborate
with other scientists;
o  Discuss prior training and how it relates to the objectives and plans of
the candidate;
o  Discuss the innovativeness and quality of the candidate's research efforts
to this point in his/her research career;
o  Letters of recommendation.  Three sealed letters of recommendation
addressing the above areas and any other evidence that the candidate has high
potential for a cancer research career.

Career Development Plan

o  Present a systematic plan that covers the mentored and unmentored phases of
this Program.  This plan should incorporate  the prior research training and
experience of the candidate to provide a basis for the need for further career
development to become an independent investigator focusing on cancer research
that is highly relevant to human biology and human disease.  The plan should
provide a description of the research and training experiences that will occur
during the mentored and unmentored phases; and must present a convincing case
that, as a result of these experiences, the candidate will have a high
probability of developing the research skills and ability needed to work in a
collaborative environment and become a successful independently supported
investigator. The plan must include a statement regarding the proposed length
of the mentored and unmentored phases;

o  Document prior instruction in or propose plans for instruction in the
responsible conduct of research in terms of subject matter and duration of

Research Plan

o  Describe the research plan using Form PHS 398 (rev. 4/98 or subsequent
revisions) following instructions for the  Specific Aims, Background and
Significance, Progress Report/Preliminary Studies, Research Design and
Methods.  The candidate should consult with the mentor regarding the
development of this section.  The research plan must be highly relevant to
human biology and human cancer disease.

Mentor's Statement

o  The application must include a statement from the mentor including
information on research qualifications and previous experience as a research
supervisor.  The applications must also include information to describe the
mentor's research support related to the candidate's research plan and nature
of the supervision that will occur during the mentored phase of the proposed
award period;
o  Similar information must be provided by any co-mentor.  If more than one
mentor is proposed, the respective areas of expertise and responsibility
should be described.

Environment and Institutional Commitment

o  Describe the resources and facilities that will be available to the
o  Describe how the research environment of the institution is particularly
suited for the development of the candidate's research career and the pursuit
of the proposed research plan;
o  In a clear statement, provide assurances that the candidate will be able to
spend a minimum of 75 percent effort in the development of his/her research
program, with the remaining percent effort spent on activities related to the
development of their research career.

Biographical Sketch

o  Biographical Sketch

A biographical sketch is required for all key personnel.  Provide information
on research projects completed and/or research grants participated in during
the last five years that are relevant to the proposed project.


Applicants using a PHS 398 Form bearing the revision date 4/98 must follow the
instructions in the form.


Applications will be reviewed for completeness by the Center for Scientific
Review and for responsiveness to this program announcement by the National
Cancer Institute.  Incomplete or non-responsive applications will be returned
to the applicant without further consideration.  Applications that are
complete and responsive to the program announcement will be evaluated for
scientific and technical merit by an appropriate scientific review group
convened by the National Cancer Institute in accordance with the standard NIH
peer review procedures.  As part of the initial merit review, all applications
will receive a written critique, and may undergo a process in which only those
applications deemed to have the highest scientific merit, generally the top
half of applications under review, will be discussed, assigned a priority
score, and receive a second level review by the National Cancer Advisory

The following review criteria will be applied:


o  Commitment of the candidate to a career in basic cancer research that will
be focused on problems highly relevant to human biology and human cancer
o  Ability of the candidate to interact and collaborate with other scientists;
o  Quality of the prior scientific training and experience, including
publications that establish the innovativeness of the candidate in research
and a high potential for an independent research career;
o  Recommendations of three well-established scientists attesting to the
special potential of the individual to pursue an independent career in cancer

Career Development Plan

o  Likelihood that the plan will contribute substantially to the scientific
development of the candidate, and the achievement of an independent research
program highly relevant to human biology and human cancer disease, based on:
- Candidate's prior training and research experience;
- Appropriateness of the goals and scope of the plan to complement prior
training/research experience and achieve the stated training and research
o  Appropriateness of the proposed durations of the mentored and unmentored
o  Appropriateness of the proposed activities during the mentored and
unmentored phases for a five year award;
o  Adequacy of prior or proposed training in the responsible conduct of

Research Plan

o  Degree of relevance of the research plan to developing an independent
research program focused on human biology and human disease as they relate to
the etiology, pathogenesis, prevention, diagnosis, and/or treatment of human
o  A sound research project that is consistent with the development plan for
an independent career in cancer research and the candidate's level of research
development must be provided (All applicants for this award will have had
previous postdoctoral research experience and in some cases may have been
Principal Investigators on small research grants);
o  Usefulness of the research plan as a vehicle for enhancing existing
research skills as described in the career development plan;
o  The originality and quality of the research hypothesis/question, design and
methodology, judged in the context of the candidate's previous training and

Mentor/ Co-Mentor

o  Appropriateness of the mentor's research qualifications in the area of the
proposed research;
o  Previous experience in fostering the development of cancer researchers;
o  History of research productivity and peer reviewed support;
o  Adequacy of support for the mentored phase of the proposed research

Institutional Environment and Commitment

o  Clear commitment of the institution to ensure that a minimum of 75 percent
of the candidate's effort will be devoted directly to research, with the
remaining percent effort being devoted to activities related to the successful
development of a research career;
o  Adequacy of research facilities and training opportunities;
o  Quality and relevance of the environment for scientific and professional
development of the candidate.


o  Justification of the requested budget in relation to career development
goals and research aims and plans.


The NCI will notify the applicant of the National Cancer Advisory Board's
(NCAB) action shortly after its meeting.  Funding decisions will be made based
on the scientific merit of the application as evaluated by the initial review
group, the results of the secondary review by the NCAB, the need for research
personnel in specific program areas, and the availability of funds.


These guidelines apply only to the non-competing year in which the transition
is requested.  Other non-competing applications should be completed in
accordance with the guidelines for streamlined (SNAP) applications outlines in
PHS form 2590.

Application Procedure:

The application procedure for the initial Howard Temin Award cannot be used
for the transition to an unmentored status.  Therefore, follow the
supplemental application guidelines below for this aspect of the Award:

Applications are to be submitted on the Application for Continuation Grant
form PHS 2590 (rev. 4/98 and subsequent revisions), including the additional
instructions for Research Career Award Applications starting on page IV-1. 
The application kit should be obtained from the grantee institution.

Submit a signed, typewritten original of the signed application and two signed
photocopies in one package to:

Records Management Center
Grants Administration
National Cancer Institute
Executive Plaza South, Suite T-42 MSC 7107
Bethesda, MD 20892-7107

Special instructions for completion of the application:

o  To associate the application with a transition request, enter "NCI HOWARD
TEMIN AWARD (K01) TRANSITION" on Line 1, Form Page 1;

o  Provide an itemized listing with associated projected costs for all items

o  Biographical Sketch (Form Page 4):  Provide for all key personnel to be
involved in the research project.  Provide information on research projects
completed and/or research grants participated in during the last five years
that are relevant to the proposed project.

o  Progress Report Summary (Form Page 5): Follow guidelines in Instructions. 
Additional instructions include:
- This section should be keep as short as possible.  However, due to the
unique reporting requirements for the "transition" application, the section
may exceed two pages;
- Studies and Results (Item b):  The information provided must clearly justify
a transition to the unmentored phase of the award;
- Plans (Item b): Follow the guidelines in the Instructions.  Additional
information to be provided is as follows:
o  Describe how the scope of the project initiated during the unmentored phase
will be changed in response to the increased level of research support
provided in the mentored phase of this award.  Provide detailed research plans
if there is a major change in research scope of the original peer reviewed
research plan;
o  Describe the relevance of the research plan to the etiology, pathogenesis,
prevention, diagnosis, and/or treatment of human cancer;
o  Describe how the proposed research and research-related activities should
contribute to the scientific development of  the candidate, and the
development of an independently funded research program;
o  Describe long term research career goals, including the timing of
submission of applications for investigator-initiated research grants;
o  Provide a statement from the Chairperson of the department to which the
awardee has been recruited describing the type of faculty position offered and
if it is a tenure-track position (or equivalent); the responsibilities of the
position; the laboratory facilities that will be provided for exclusive use by
the awardee, and the relationship of these facilities to the laboratories of
the applicant's mentor (if the transition does not involve a change of
sponsoring institution); additional non-PHS research related
departmental/institutional support that will be provided for technical support
staff, equipment, animals, etc; relationship of the awardee's research program
to ongoing programs within the department; career plans for the awardee;
o  Provide a statement from the institution ensuring that a minimum of 75
percent of the candidate's effort will be devoted directly to research, with
the remaining percent effort being devoted to activities related to the
successful development of a research career;
o  If the transition involves a change of sponsoring institution, the new
institution must additionally document a strong, well-established program in
biomedical research related to cancer, including a high quality research
environment with staff capable of productive collaboration with the candidate.


o  Provide a sealed statement from the mentor recommending the candidate for
the transition.  This recommendation should be based on the scientific
productivity of the candidate under his/her mentorship, and on the mentor's
detailed evaluation that the candidate is ready to develop an innovative and
independently-supported research program.  This letter should be mailed
directly to the NCI Program Director for the candidate's Howard Temin Award.

Review Considerations for a "Transition" Application:

Applications received will require NCI staff approval before the transition
award to an independent position is activated.  Depending upon the scope of
changes in the research plan as compared with the original peer reviewed grant
application, the application could receive a second level of review by an 
IRG.  Approval will be based upon the following criteria:

o  The mentor's support of the candidate;
o  The clear relevance of the new Research Plan to human biology and human
disease as they relate to cancer etiology, pathogenesis, prevention, control,
diagnosis and treatment;
o  The soundness of the "Letter of Commitment" from the institution, to
provide the candidate with protected time (no less than 75 percent effort
dedicated to the development of a research program with the remaining effort
to be used in research related activities) and describing arrangements with
the candidate providing a permanent preferably tenure-track position, adequate
facilities for conducting a research program, and additional resources
conducive to the development of a research project and establishment of a
successful research career;
o  The adequacy of the plans for inclusion of women, children, and minorities
in any clinical or population research activities, as applicable;
o  The adequacy of the proposed protection of humans, animals or the
environment to the extent that they may be adversely affected by the
activities proposed in this application.

Award Criteria for a "Transition" Application:

Funding decisions will be made by NCI program staff based on satisfying the
review considerations above.  NCI program staff will notify the applicant for
the transition to unmentored status of their  action on the application.  The
transition to the unmentored phase will take effect on the anniversary date of
the grant.


Inquiries are encouraged.  The opportunity to clarify any issues or questions
from potential applicants is welcome.  Refer to: for additional guidelines on career
development opportunities supported by the National Cancer Institute.

Direct inquiries regarding programmatic issues to:

Dr. Andrew Vargosko
Office of Centers, Training and Resources
National Cancer Institute
Executive Plaza North, Room 520, MSC 7390
Bethesda, MD  20892-7390
Telephone:  (301) 496-8580
FAX:  (301) 402-4472

Inquiries regarding fiscal matters may be directed to:

Ms. Catherine Blount
Office of Administrative Management
National Cancer Institute
Executive Plaza South, Room 243
Bethesda, MD  20892
Telephone:  (301) 496-7800 ext. 262
FAX:  (301) 496-8601

Direct inquiries regarding review matters to:

Ms. Toby Friedberg
Division of Extramural Activities
National Cancer Institute
6130 Executive Boulevard, Room 636, MSC-7407
Bethesda, MD  20892-7407
Rockville, MD  20852 (for express/courier service)
Telephone:  (301) 496-3428
FAX:  (301) 402-0275


This program is described in the Catalog of Federal Domestic Assistance No.
93.398 Cancer Research Manpower.  Awards are made under authorization of the
Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by
Public Law 99-158, 42 USC 241 and 285) and administered under PHS grants
policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74 and part 92. 
This program is not subject to the intergovernmental review requirements of
Executive Order 12372 or Health Systems Agency review.

The PHS strongly encourages all grant and contract recipients to provide a
smoke-free workplace and promote the non-use of all tobacco products.  In
addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking
in certain facilities (or in some cases, any portion of a facility) in which
regular or routine education, library, day care, health care or early
childhood development services are provided to children.  This is consistent
with the PHS mission to protect and advance the physical and mental health of
the American people.

Return to Volume Index

Return to NIH Guide Main Index

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS) - Government Made Easy

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.